 | • レポートコード：MRC2312MG02111 • 出版社/出版日：Market Monitor Global / 2023年12月 • レポート形態：英文、PDF、99ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品 |
| Single User | ￥487,500 (USD3,250) | ▷ お問い合わせ |
| Enterprise User | ￥731,250 (USD4,875) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査レポートは次の情報を含め、世界の乳幼児用混合ワクチン市場規模と予測を収録しています。・世界の乳幼児用混合ワクチン市場：売上、2018年-2023年、2024年-2029年 ・世界の乳幼児用混合ワクチン市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界の乳幼児用混合ワクチン市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「5種混合ワクチン」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 乳幼児用混合ワクチンのグローバル主要企業は、Sanofi、 GSK、 Mitsubishi Tanabe Pharma、 KM Biologics、 Wuhan Institute of Biological Products、 Walvax Biotechnology、 Chengdu Institute of Biological Products、 Minhai Biotechnologyなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、乳幼児用混合ワクチンのメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界の乳幼児用混合ワクチン市場：タイプ別、2018年-2023年、2024年-2029年 世界の乳幼児用混合ワクチン市場：タイプ別市場シェア、2022年 ・5種混合ワクチン、4種混合ワクチン、3種混合ワクチン、その他 世界の乳幼児用混合ワクチン市場：用途別、2018年-2023年、2024年-2029年 世界の乳幼児用混合ワクチン市場：用途別市場シェア、2022年 ・12ヶ月以下、12ヶ月以上 世界の乳幼児用混合ワクチン市場：地域・国別、2018年-2023年、2024年-2029年 世界の乳幼児用混合ワクチン市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業における乳幼児用混合ワクチンのグローバル売上、2018年-2023年 ・主要企業における乳幼児用混合ワクチンのグローバル売上シェア、2022年 ・主要企業における乳幼児用混合ワクチンのグローバル販売量、2018年-2023年 ・主要企業における乳幼児用混合ワクチンのグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 Sanofi、 GSK、 Mitsubishi Tanabe Pharma、 KM Biologics、 Wuhan Institute of Biological Products、 Walvax Biotechnology、 Chengdu Institute of Biological Products、 Minhai Biotechnology ************************************************************* ・調査・分析レポートの概要 乳幼児用混合ワクチン市場の定義 市場セグメント 世界の乳幼児用混合ワクチン市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界の乳幼児用混合ワクチン市場規模 世界の乳幼児用混合ワクチン市場規模：2022年 VS 2029年 世界の乳幼児用混合ワクチン市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでの乳幼児用混合ワクチンの売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業の乳幼児用混合ワクチン製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：5種混合ワクチン、4種混合ワクチン、3種混合ワクチン、その他 乳幼児用混合ワクチンのタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：12ヶ月以下、12ヶ月以上 乳幼児用混合ワクチンの用途別グローバル売上・予測 ・地域別市場分析 地域別乳幼児用混合ワクチン市場規模 2022年と2029年 地域別乳幼児用混合ワクチン売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） Sanofi、 GSK、 Mitsubishi Tanabe Pharma、 KM Biologics、 Wuhan Institute of Biological Products、 Walvax Biotechnology、 Chengdu Institute of Biological Products、 Minhai Biotechnology ... |
This research report provides a comprehensive analysis of the Infant and Child Multiple Vaccine market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Infant and Child Multiple Vaccine market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Infant and Child Multiple Vaccine, challenges faced by the industry, and potential opportunities for market players.
The global Infant and Child Multiple Vaccine market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Infant and Child Multiple Vaccine market presents opportunities for various stakeholders, including 12 Months Below, 12 Months Above. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Infant and Child Multiple Vaccine market. Additionally, the growing consumer demand present avenues for market expansion.
The global Infant and Child Multiple Vaccine market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period.
The process of upgrading global multi-vaccine products is a process of solidifying the competitive landscape.
Key Features:
The research report on the Infant and Child Multiple Vaccine market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Infant and Child Multiple Vaccine market.
Market Overview: The report provides a comprehensive overview of the Infant and Child Multiple Vaccine market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Pentavalent Vaccine, Quadruple Vaccine), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Infant and Child Multiple Vaccine market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Infant and Child Multiple Vaccine market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Infant and Child Multiple Vaccine market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Infant and Child Multiple Vaccine market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Infant and Child Multiple Vaccine market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Infant and Child Multiple Vaccine market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Infant and Child Multiple Vaccine, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Infant and Child Multiple Vaccine market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Infant and Child Multiple Vaccine market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Pentavalent Vaccine
Quadruple Vaccine
Triple Vaccine
Others
Market segment by Application
12 Months Below
12 Months Above
Global Infant and Child Multiple Vaccine Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Sanofi
GSK
Mitsubishi Tanabe Pharma
KM Biologics
Wuhan Institute of Biological Products
Walvax Biotechnology
Chengdu Institute of Biological Products
Minhai Biotechnology
Outline of Major Chapters:
Chapter 1: Introduces the definition of Infant and Child Multiple Vaccine, market overview.
Chapter 2: Global Infant and Child Multiple Vaccine market size in revenue and volume.
Chapter 3: Detailed analysis of Infant and Child Multiple Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Infant and Child Multiple Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Infant and Child Multiple Vaccine capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 Infant and Child Multiple Vaccine Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Infant and Child Multiple Vaccine Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Infant and Child Multiple Vaccine Overall Market Size
2.1 Global Infant and Child Multiple Vaccine Market Size: 2022 VS 2029
2.2 Global Infant and Child Multiple Vaccine Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Infant and Child Multiple Vaccine Sales: 2018-2029
3 Company Landscape
3.1 Top Infant and Child Multiple Vaccine Players in Global Market
3.2 Top Global Infant and Child Multiple Vaccine Companies Ranked by Revenue
3.3 Global Infant and Child Multiple Vaccine Revenue by Companies
3.4 Global Infant and Child Multiple Vaccine Sales by Companies
3.5 Global Infant and Child Multiple Vaccine Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Infant and Child Multiple Vaccine Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Infant and Child Multiple Vaccine Product Type
3.8 Tier 1, Tier 2 and Tier 3 Infant and Child Multiple Vaccine Players in Global Market
3.8.1 List of Global Tier 1 Infant and Child Multiple Vaccine Companies
3.8.2 List of Global Tier 2 and Tier 3 Infant and Child Multiple Vaccine Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Infant and Child Multiple Vaccine Market Size Markets, 2022 & 2029
4.1.2 Pentavalent Vaccine
4.1.3 Quadruple Vaccine
4.1.4 Triple Vaccine
4.1.5 Others
4.2 By Type – Global Infant and Child Multiple Vaccine Revenue & Forecasts
4.2.1 By Type – Global Infant and Child Multiple Vaccine Revenue, 2018-2023
4.2.2 By Type – Global Infant and Child Multiple Vaccine Revenue, 2024-2029
4.2.3 By Type – Global Infant and Child Multiple Vaccine Revenue Market Share, 2018-2029
4.3 By Type – Global Infant and Child Multiple Vaccine Sales & Forecasts
4.3.1 By Type – Global Infant and Child Multiple Vaccine Sales, 2018-2023
4.3.2 By Type – Global Infant and Child Multiple Vaccine Sales, 2024-2029
4.3.3 By Type – Global Infant and Child Multiple Vaccine Sales Market Share, 2018-2029
4.4 By Type – Global Infant and Child Multiple Vaccine Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Infant and Child Multiple Vaccine Market Size, 2022 & 2029
5.1.2 12 Months Below
5.1.3 12 Months Above
5.2 By Application – Global Infant and Child Multiple Vaccine Revenue & Forecasts
5.2.1 By Application – Global Infant and Child Multiple Vaccine Revenue, 2018-2023
5.2.2 By Application – Global Infant and Child Multiple Vaccine Revenue, 2024-2029
5.2.3 By Application – Global Infant and Child Multiple Vaccine Revenue Market Share, 2018-2029
5.3 By Application – Global Infant and Child Multiple Vaccine Sales & Forecasts
5.3.1 By Application – Global Infant and Child Multiple Vaccine Sales, 2018-2023
5.3.2 By Application – Global Infant and Child Multiple Vaccine Sales, 2024-2029
5.3.3 By Application – Global Infant and Child Multiple Vaccine Sales Market Share, 2018-2029
5.4 By Application – Global Infant and Child Multiple Vaccine Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Infant and Child Multiple Vaccine Market Size, 2022 & 2029
6.2 By Region – Global Infant and Child Multiple Vaccine Revenue & Forecasts
6.2.1 By Region – Global Infant and Child Multiple Vaccine Revenue, 2018-2023
6.2.2 By Region – Global Infant and Child Multiple Vaccine Revenue, 2024-2029
6.2.3 By Region – Global Infant and Child Multiple Vaccine Revenue Market Share, 2018-2029
6.3 By Region – Global Infant and Child Multiple Vaccine Sales & Forecasts
6.3.1 By Region – Global Infant and Child Multiple Vaccine Sales, 2018-2023
6.3.2 By Region – Global Infant and Child Multiple Vaccine Sales, 2024-2029
6.3.3 By Region – Global Infant and Child Multiple Vaccine Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Infant and Child Multiple Vaccine Revenue, 2018-2029
6.4.2 By Country – North America Infant and Child Multiple Vaccine Sales, 2018-2029
6.4.3 US Infant and Child Multiple Vaccine Market Size, 2018-2029
6.4.4 Canada Infant and Child Multiple Vaccine Market Size, 2018-2029
6.4.5 Mexico Infant and Child Multiple Vaccine Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Infant and Child Multiple Vaccine Revenue, 2018-2029
6.5.2 By Country – Europe Infant and Child Multiple Vaccine Sales, 2018-2029
6.5.3 Germany Infant and Child Multiple Vaccine Market Size, 2018-2029
6.5.4 France Infant and Child Multiple Vaccine Market Size, 2018-2029
6.5.5 U.K. Infant and Child Multiple Vaccine Market Size, 2018-2029
6.5.6 Italy Infant and Child Multiple Vaccine Market Size, 2018-2029
6.5.7 Russia Infant and Child Multiple Vaccine Market Size, 2018-2029
6.5.8 Nordic Countries Infant and Child Multiple Vaccine Market Size, 2018-2029
6.5.9 Benelux Infant and Child Multiple Vaccine Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Infant and Child Multiple Vaccine Revenue, 2018-2029
6.6.2 By Region – Asia Infant and Child Multiple Vaccine Sales, 2018-2029
6.6.3 China Infant and Child Multiple Vaccine Market Size, 2018-2029
6.6.4 Japan Infant and Child Multiple Vaccine Market Size, 2018-2029
6.6.5 South Korea Infant and Child Multiple Vaccine Market Size, 2018-2029
6.6.6 Southeast Asia Infant and Child Multiple Vaccine Market Size, 2018-2029
6.6.7 India Infant and Child Multiple Vaccine Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Infant and Child Multiple Vaccine Revenue, 2018-2029
6.7.2 By Country – South America Infant and Child Multiple Vaccine Sales, 2018-2029
6.7.3 Brazil Infant and Child Multiple Vaccine Market Size, 2018-2029
6.7.4 Argentina Infant and Child Multiple Vaccine Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Infant and Child Multiple Vaccine Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Infant and Child Multiple Vaccine Sales, 2018-2029
6.8.3 Turkey Infant and Child Multiple Vaccine Market Size, 2018-2029
6.8.4 Israel Infant and Child Multiple Vaccine Market Size, 2018-2029
6.8.5 Saudi Arabia Infant and Child Multiple Vaccine Market Size, 2018-2029
6.8.6 UAE Infant and Child Multiple Vaccine Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Sanofi
7.1.1 Sanofi Company Summary
7.1.2 Sanofi Business Overview
7.1.3 Sanofi Infant and Child Multiple Vaccine Major Product Offerings
7.1.4 Sanofi Infant and Child Multiple Vaccine Sales and Revenue in Global (2018-2023)
7.1.5 Sanofi Key News & Latest Developments
7.2 GSK
7.2.1 GSK Company Summary
7.2.2 GSK Business Overview
7.2.3 GSK Infant and Child Multiple Vaccine Major Product Offerings
7.2.4 GSK Infant and Child Multiple Vaccine Sales and Revenue in Global (2018-2023)
7.2.5 GSK Key News & Latest Developments
7.3 Mitsubishi Tanabe Pharma
7.3.1 Mitsubishi Tanabe Pharma Company Summary
7.3.2 Mitsubishi Tanabe Pharma Business Overview
7.3.3 Mitsubishi Tanabe Pharma Infant and Child Multiple Vaccine Major Product Offerings
7.3.4 Mitsubishi Tanabe Pharma Infant and Child Multiple Vaccine Sales and Revenue in Global (2018-2023)
7.3.5 Mitsubishi Tanabe Pharma Key News & Latest Developments
7.4 KM Biologics
7.4.1 KM Biologics Company Summary
7.4.2 KM Biologics Business Overview
7.4.3 KM Biologics Infant and Child Multiple Vaccine Major Product Offerings
7.4.4 KM Biologics Infant and Child Multiple Vaccine Sales and Revenue in Global (2018-2023)
7.4.5 KM Biologics Key News & Latest Developments
7.5 Wuhan Institute of Biological Products
7.5.1 Wuhan Institute of Biological Products Company Summary
7.5.2 Wuhan Institute of Biological Products Business Overview
7.5.3 Wuhan Institute of Biological Products Infant and Child Multiple Vaccine Major Product Offerings
7.5.4 Wuhan Institute of Biological Products Infant and Child Multiple Vaccine Sales and Revenue in Global (2018-2023)
7.5.5 Wuhan Institute of Biological Products Key News & Latest Developments
7.6 Walvax Biotechnology
7.6.1 Walvax Biotechnology Company Summary
7.6.2 Walvax Biotechnology Business Overview
7.6.3 Walvax Biotechnology Infant and Child Multiple Vaccine Major Product Offerings
7.6.4 Walvax Biotechnology Infant and Child Multiple Vaccine Sales and Revenue in Global (2018-2023)
7.6.5 Walvax Biotechnology Key News & Latest Developments
7.7 Chengdu Institute of Biological Products
7.7.1 Chengdu Institute of Biological Products Company Summary
7.7.2 Chengdu Institute of Biological Products Business Overview
7.7.3 Chengdu Institute of Biological Products Infant and Child Multiple Vaccine Major Product Offerings
7.7.4 Chengdu Institute of Biological Products Infant and Child Multiple Vaccine Sales and Revenue in Global (2018-2023)
7.7.5 Chengdu Institute of Biological Products Key News & Latest Developments
7.8 Minhai Biotechnology
7.8.1 Minhai Biotechnology Company Summary
7.8.2 Minhai Biotechnology Business Overview
7.8.3 Minhai Biotechnology Infant and Child Multiple Vaccine Major Product Offerings
7.8.4 Minhai Biotechnology Infant and Child Multiple Vaccine Sales and Revenue in Global (2018-2023)
7.8.5 Minhai Biotechnology Key News & Latest Developments
8 Global Infant and Child Multiple Vaccine Production Capacity, Analysis
8.1 Global Infant and Child Multiple Vaccine Production Capacity, 2018-2029
8.2 Infant and Child Multiple Vaccine Production Capacity of Key Manufacturers in Global Market
8.3 Global Infant and Child Multiple Vaccine Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Infant and Child Multiple Vaccine Supply Chain Analysis
10.1 Infant and Child Multiple Vaccine Industry Value Chain
10.2 Infant and Child Multiple Vaccine Upstream Market
10.3 Infant and Child Multiple Vaccine Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Infant and Child Multiple Vaccine Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
